Rxulti

RSS

brexpiprazole

Authorised
This medicine is authorised for use in the European Union.

Overview

Rxulti is an antipsychotic medicine used to treat schizophrenia in adults. Schizophrenia is a mental illness with symptoms such as delusions, disorganised thinking and speech, suspiciousness and hallucinations (seeing, hearing or feeling things that are not there).

Rxulti contains the active substance brexpiprazole.

This EPAR was last updated on 26/11/2018

Authorisation details

Product details
Name
Rxulti
Agency product number
EMEA/H/C/003841
Active substance
brexpiprazole
International non-proprietary name (INN) or common name
brexpiprazole
Therapeutic area (MeSH)
Schizophrenia
Anatomical therapeutic chemical (ATC) code
N05AX16
Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Otsuka Pharmaceutical Europe Ltd
Revision
0
Date of issue of marketing authorisation valid throughout the European Union
26/07/2018
Contact address

Gallions
Wexham Springs
Framewood Road
Wexham SL3 6PJ
United Kingdom

Product information

26/07/2018 Rxulti - EMEA/H/C/003841 - -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Psycholeptics

Therapeutic indication

Treatment of schizophrenia.

Assessment history

How useful was this page?

Add your rating